Dong-Sheng Chen
Overview
Explore the profile of Dong-Sheng Chen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
42
Citations
158
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chen Z, Zhang J, He P, Xiong T, Zhu D, Zhu W, et al.
J Virol
. 2025 Jan;
99(2):e0172724.
PMID: 39745436
Emerging tick-borne orthonairovirus infections pose a growing global concern, with limited understanding of the viral ovarian tumor-like cysteine proteases (vOTUs) encoded by novel orthonairoviruses. These vOTUs, a group of deubiquinylases...
2.
Jia W, Fan M, Chen D, Sun L, Wang H, Chao B
Ying Yong Sheng Tai Xue Bao
. 2024 Sep;
35(6):1509-1517.
PMID: 39235008
We established a mixed-effects model incorporating climatic factors for the base diameter and length of the primary branches of using stepwise regression, based on climatic data from a total of...
3.
Wang W, Chen D, Guo Z, Yu D, Cao Q, Zhu X
World J Clin Cases
. 2023 Dec;
11(33):8003-8012.
PMID: 38075574
Background: The recovery time of hand wounds is long, which can easily result in chronic and refractory wounds, making the wounds unable to be properly repaired. The treatment cycle is...
4.
Gong X, Chen H, Lu Z, Zhu C, Chen D, Chen X
Invest New Drugs
. 2023 May;
41(3):376-379.
PMID: 37129839
No abstract available.
5.
Zeng T, Yang G, Lou C, Wei W, Tao C, Chen X, et al.
Nat Commun
. 2023 Mar;
14(1):1340.
PMID: 36906670
The prognosis of biliary tract cancer (BTC) remains unsatisfactory. This single-arm, phase II clinical trial (ChiCTR2000036652) investigated the efficacy, safety, and predictive biomarkers of sintilimab plus gemcitabine and cisplatin as...
6.
Yang F, Jing J, Fu S, Su X, Zhong Y, Chen D, et al.
Mol Neurobiol
. 2023 Jan;
60(4):2086-2098.
PMID: 36602702
Central post-stroke pain (CPSP) is a highly refractory form of central neuropathic pain that has been poorly studied mechanistically. Recent observations have emphasized the critical role of the spinal dorsal...
7.
Zeng T, Pan Y, Yuan Z, Chen D, Song Y, Gao Y
Front Immunol
. 2022 Sep;
13:943066.
PMID: 36159865
Background: Immune checkpoint inhibitor (ICI)-combined chemotherapy in advanced intrahepatic cholangiocarcinoma has been proved to have more efficacy in a series of clinical trials. However, whether the tumor microenvironment (TME) plays...
8.
Tong Y, Chen D, Feng J, Gao H
Ying Yong Sheng Tai Xue Bao
. 2022 Sep;
33(9):2321-2330.
PMID: 36131646
Crown width is a critical variable in reflecting the individual tree growth status and in developing forest growth and yield models. With the crown width base model as reference, we...
9.
Ma P, Huang R, Gu Y, Fang Y, Wu X, Chen D, et al.
Anticancer Drugs
. 2022 Aug;
33(10):1186-1190.
PMID: 35946569
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) have significantly improved response in all stages of patients with EGFR positive mutations in nonsmall cell lung cancer. However, the primary resistance mechanism...
10.
Gong X, Chen H, Zhang L, Chen D, Li W, Chen D, et al.
Front Immunol
. 2022 Aug;
13:920253.
PMID: 35911687
Background: Patients with early-stage laryngeal cancer, even stage T1-2N0, are at considerable risk of recurrence and death. The genetic and immunologic characteristics of recurrent laryngeal cancer remain unclear. Methods: A...